Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase 2 study found.
Phase 2 trial results suggests abiraterone used in combination in cabazitaxel in men with chemotherapy-naïve metastatic castration-resistant prostate cancer might prolong radiographic progression-free survival compared with abiraterone alone.
Despite the introduction in recent year of promising novel agents, men with newly diagnosed metastatic prostate cancer have experienced only a slight decline in death risk.
A new analysis of men in the CARD study showed that cabazitaxel improved pain response and decreased the likelihood of pain progression compared with either abiraterone or enzalutamide.
In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.
PSA levels of 50 ng/mL or above vs 20 to 49.9 ng/mL prior to radical prostatectomy for high-risk clinically localized prostate cancer are associated with an increased risk of biochemical recurrence, metastasis, and cancer-related death, a study found.
In a study of men with prostate cancer, the presence of pre-existing cardiovascular diseases was associated with higher risk of death from taking certain medications.
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
The primary end point was radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic disease progression at any time or death within 24 weeks after drug discontinuation.
For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.
Even though the EMBRACE study adds to the literature, according to authors the “best way” to screen men with germline DNA damage repair abnormalities “remains unclear.”
